Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1970 3
1972 4
1973 1
1975 3
1976 3
1977 1
1978 1
1979 4
1980 3
1981 1
1983 1
1984 2
1985 1
1986 3
1987 1
1988 1
1989 2
1990 4
1991 7
1992 6
1993 2
1994 5
1995 1
1996 4
1997 3
1998 5
1999 7
2000 5
2001 6
2002 2
2003 6
2004 4
2005 4
2006 10
2007 11
2008 15
2009 12
2010 21
2011 10
2012 5
2013 9
2014 11
2015 14
2016 24
2017 14
2018 20
2019 25
2020 45
2021 53
2022 51
2023 37

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Results by year

Filters applied: . Clear all
Page 1
Integrating genomic features for non-invasive early lung cancer detection.
Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Loo BW Jr, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M. Chabon JJ, et al. Among authors: ko rb. Nature. 2020 Apr;580(7802):245-251. doi: 10.1038/s41586-020-2140-0. Epub 2020 Mar 25. Nature. 2020. PMID: 32269342 Free PMC article.
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez DR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo BW Jr, Lin SH, Alizadeh AA, Diehn M. Moding EJ, et al. Among authors: ko rb. Nat Cancer. 2020 Feb;1(2):176-183. doi: 10.1038/s43018-019-0011-0. Epub 2020 Jan 20. Nat Cancer. 2020. PMID: 34505064 Free PMC article.
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M. Nabet BY, et al. Among authors: ko rb. Cell. 2020 Oct 15;183(2):363-376.e13. doi: 10.1016/j.cell.2020.09.001. Epub 2020 Oct 1. Cell. 2020. PMID: 33007267 Free PMC article.
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.
Binkley MS, Jeon YJ, Nesselbush M, Moding EJ, Nabet BY, Almanza D, Kunder C, Stehr H, Yoo CH, Rhee S, Xiang M, Chabon JJ, Hamilton E, Kurtz DM, Gojenola L, Owen SG, Ko RB, Shin JH, Maxim PG, Lui NS, Backhus LM, Berry MF, Shrager JB, Ramchandran KJ, Padda SK, Das M, Neal JW, Wakelee HA, Alizadeh AA, Loo BW Jr, Diehn M. Binkley MS, et al. Among authors: ko rb. Cancer Discov. 2020 Dec;10(12):1826-1841. doi: 10.1158/2159-8290.CD-20-0282. Epub 2020 Oct 18. Cancer Discov. 2020. PMID: 33071215 Free PMC article.
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jiménez-Yuste V. Kruse-Jarres R, et al. Among authors: ko rh. Blood Adv. 2022 Dec 27;6(24):6140-6150. doi: 10.1182/bloodadvances.2022007458. Blood Adv. 2022. PMID: 35939785 Free PMC article.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: ko r. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
Ko R, Wilson RD, Loscutoff S. Ko R, et al. Urology. 2003 Jun;61(6):1292. doi: 10.1016/s0090-4295(02)02508-6. Urology. 2003. PMID: 12809931 No abstract available.
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K. Saito R, et al. Among authors: ko r. Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2. Eur J Cancer. 2023. PMID: 36966696 Free article. Clinical Trial.
448 results